The estimated Net Worth of Richard M. Toselli is at least $1.26 Milhão dollars as of 10 March 2020. Richard Toselli owns over 3,636 units of InVivo Therapeutics Corp stock worth over $1,942 and over the last 7 years he sold NVIV stock worth over $5,072. In addition, he makes $1,257,090 as President, Chief Executive Officer, Director, e Chief Medical Officer at InVivo Therapeutics Corp.
Richard has made over 2 trades of the InVivo Therapeutics Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,636 units of NVIV stock worth $1,164 on 10 March 2020.
The largest trade he's ever made was selling 5,229 units of InVivo Therapeutics Corp stock on 4 June 2019 worth over $5,072. On average, Richard trades about 493 units every 16 days since 2017. As of 10 March 2020 he still owns at least 6,069 units of InVivo Therapeutics Corp stock.
You can see the complete history of Richard Toselli stock trades at the bottom of the page.
Dr. Richard Toselli M.D. serves as President, Chief Executive Officer, Director, Chief Medical Officer of the Company. Prior to being appointed President and Chief Executive Officer and a director, Dr. Toselli served as our Acting Chief Executive Officer from December 2017 to February 2018. Since July 2017, Dr. Toselli has also served as our Chief Medical Officer. Before joining the company, Dr. Toselli served as the Chief Medical Officer for Cochlear Limited, a medical device company, from June 2016 until March 2017. Prior to that, Dr. Toselli served at Sanofi, a pharmaceutical company, from July 2012 to June 2016 in various levels of increasing responsibility, including Vice President of Global Medical Affairs — Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Public Limited Company (now Medtronic Public Limited Company), a medical device company, and earlier held the position of Vice President of Evidence-Based Medicine for the device sector at Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturing company. Prior to that, Dr. Toselli held various roles at DePuy Synthes Spine, Inc., a medical device company, including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. Dr. Toselli holds a Bachelor of Arts from Providence College, his medical degree from Brown University, and a Master of Business Administration from the UNC’s Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon. Dr. Toselli brings to our Board a significant amount of experience in medical and regulatory affairs, as well as a deep understanding of neurosurgery, medical devices and the science and technology involved in our business.
As the President, Chief Executive Officer, Director, e Chief Medical Officer of InVivo Therapeutics Corp, the total compensation of Richard Toselli at InVivo Therapeutics Corp is $1,257,090. There are no executives at InVivo Therapeutics Corp getting paid more.
Richard Toselli is 62, he's been the President, Chief Executive Officer, Director, e Chief Medical Officer of InVivo Therapeutics Corp since 2018. There are 8 older and 3 younger executives at InVivo Therapeutics Corp. The oldest executive at InVivo Therapeutics Holdings Corp is Richard Roberts, 76, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O INVIVO THERAPEUTICS HOLDINGS CORP., ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE, MA, 02139.
Over the last 14 years, insiders at InVivo Therapeutics Corp have traded over $11,891,061 worth of InVivo Therapeutics Corp stock and bought 364,908 units worth $191,940 . The most active insiders traders include Francis Reynolds, Robert Langer, eSean F. Moran. On average, InVivo Therapeutics Corp executives and independent directors trade stock every 24 days with the average trade being worth of $10,438. The most recent stock trade was executed by Brice Foose on 5 February 2023, trading 330,000 units of NVIV stock currently worth $122,100.
about invivo therapeutics invivo therapeutics holdings corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. the company was founded in 2005 with proprietary technology co-invented by robert langer, sc.d., professor at massachusetts institute of technology, and joseph p. vacanti, m.d., who then was at boston children’s hospital and who now is affiliated with massachusetts general hospital. in 2011, the company earned the david s. apple award from the american spinal injury association for its outstanding contribution to spinal cord injury medicine. in 2015, the company’s investigational neuro-spinal scaffold received the 2015 becker’s healthcare spine device award. the publicly-traded company is headquartered in cambridge, ma. for more details, visit www.invivotherapeutics.com. about the neuro-spinal scaffold™ following acute spinal cord injury, surgical implantation of the biodegradable neuro-spinal scaffold wi
InVivo Therapeutics Corp executives and other stock owners filed with the SEC include: